Loading
German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST.
Sebastian Bauer leads the sarcoma programme at the West German Cancer Center in Essen. He was first author of the 2022 Journal of Clinical Oncology report of INTRIGUE, the phase 3 trial that found ripretinib was not superior to sunitinib in progression-free survival after imatinib in advanced gastrointestinal stromal tumour, though it was better tolerated. His laboratory studies resistance mechanisms in GIST.
| Title | Journal | Year |
|---|---|---|
| INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib | Journal of Clinical Oncology | 2022 |
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tags gist, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tags gist, sarcoma.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.